🦻️ Invest in Doppler Labs here.
Who I Am: And Why I’m Writing This
I’m Dr. Kirk Adams, PhD, strategic advisor to Doppler Labs and a shareholder. I am writing this piece to explain why I’m investing my time and reputation in Doppler’s at-home hearing platform and the current Netcapital campaign, and to invite the right partners to help us scale responsible access.
This article is for leaders in healthcare, accessibility, HR/benefits, philanthropy, impact investing, and public policy who care about measurable inclusion and scalable health access. I approach this work from a systems-and-operations vantage point: clear problem definition, practical solutions, and accountability for outcomes. Expect both mission and mechanics, not marketing, and a direct conversation about what it takes to expand access responsibly while building durable adoption.
The Sound Of Inclusion: And Why Access Tech Wins When It Goes Home
Picture three moments that can change a life: a grandchild’s first words, a decisive boardroom exchange, a stranger asking for directions at a bus stop. In each, the choice to engage, or to withdraw, happens in seconds, not in clinics. That’s the real battleground for hearing access.
For too many people, the alternative is months of appointments, an average outlay around $4,000 for a pair, and devices that too often end up in drawers. The promise I’m backing is simple: audiologist-grade results at home in five to ten minutes, priced like a utility and supported like a service. Bring the fitting to where life happens, remove friction, and utilization follows, that’s inclusion as a strategic advantage.
Thesis & Objectives: Bring Hearing Home, At Scale, With Accountability
When you shift clinical-grade hearing from the clinic to the home, you remove the bottlenecks that suppress adoption and unlock measurable gains in health, productivity, and dignity, first in the U.S., then in countries with few or no audiologists.
Here’s what I’ll do in this piece: show the size and structure of the problem the status quo can’t solve; explain what makes Doppler’s platform different and verifiable; lay out the go-to-market, economics, and support model; detail the nonprofit arm I’ll help stand up to reach underserved regions; and invite readers to back the Netcapital raise before November 14, 2025.
The Unmet Need: And Why The Legacy Channel Can’t Reach It
The numbers tell a plain story: 1.5 billion people live with hearing loss globally; in the U.S., about 13% of adults are affected, yet usage lags far behind need. The conventional path, multiple office visits over months and an average out-of-pocket around $4,000 per pair, helps explain why roughly 38% of hearing aids end up in drawers instead of on ears. A handful of manufacturers dominate the market and sell primarily through audiologists and government channels, which concentrates access where clinical infrastructure already exists. Outside the U.S. and EU, countries like India and Mexico have fewer than about 2,000 registered audiologists each; in many regions there are none within a day’s travel. Roughly 80% of people with hearing loss live where audiologist access is limited or absent, so the incumbent channel structurally bypasses most of the world.
Over-the-counter devices have expanded choice, but many are still consumer-grade with limited processing power and battery life compared to clinical-grade aids, so adoption and satisfaction remain uneven. Audiologists are essential for complex cases; the real question is how to serve mild to moderate loss at scale without months of appointments. Until we change where and how fitting happens, we’ll keep paying more, waiting longer, and watching devices collect dust instead of delivering the conversations, safety, and productivity people need every day.
What’s Different About Doppler: Product, Proof Points, And Support
Doppler mixes accessibility into the batter, not the frosting: clinical-grade hearing aids (three styles, including all-day BTE) paired with Jenn, a handheld tablet running patented software that tunes to your preferences in about five to ten minutes and saves up to eight listening profiles. Accessories are included, 24/7 chat and extended phone support backstop the experience, and the fitting happens where life happens, at home, at work, or on the go, so people adjust faster and keep using what they buy rather than relegating it to a drawer.
The model is simple on purpose: direct-to-consumer pricing listed at $199 down plus $29 per month after a trial, with worn-out devices replaced at no charge for subscribers; retail and special channels mirror this approach. For diligence-minded readers, Doppler cites completed clinical trials, four issued utility patents, and a beta state for hardware and software, with the offering page linking to the Form C and CPA-reviewed financials. Inclusion becomes a strategic advantage when the product, support, and economics line up this cleanly.
How This Goes To Market: And Why That Matters For Equity And Economics
We’re meeting people where they are. The plan includes direct-to-consumer, big-box retail such as Walmart and Walgreens, and special channels like the VA, buying groups, and international partnerships. That multi-channel reach is the equity strategy: bring clinic-grade capability home, widen the funnel, cut drop-off, and reach workers and families who would otherwise defer care. Inclusion isn’t charity, it’s how you grow responsibly and build durable unit economics.
Reasonable questions deserve clear answers. Will at-home tuning match outcomes for everyone? Doppler targets mild to moderate loss, enables multiple listening profiles, and layers 24/7 chat with extended phone support; complex cases still belong in clinical hands. Will retailers embrace subscriptions? The plan anticipates bundled months at the point of sale to align incentives and reduce friction. The through-line is simple: reduce steps, increase stickiness, and make the path to hearing as familiar as buying any essential service.
The Nonprofit Arm: Reaching Places With Few Or No Audiologists
Here’s the next piece of the architecture: a dedicated nonprofit to deploy Doppler’s technology in developing countries where clinics are scarce. We’ll build four-sector coalitions, ministries of health, NGOs, vocational rehabilitation systems, and community organizations, and train local facilitators to deliver consistent outcomes. Jenn becomes the standardizer: the same quick-tune workflow, translation, and offline operation, with remote escalation to licensed professionals where available. The focus is mild to moderate loss, delivered where people live and work, in the regions the incumbent channel doesn’t reach.
Execution matters. We’ll measure time-to-tune, device retention and daily use, and functional results like keeping a student in class or a worker on the job. Distribution will be paired with workforce pathways because access to hearing unlocks access to employment. Safeguards include informed consent, referral networks for complex cases, device maintenance programs, and local data stewardship. We’ll publish results openly and invite third-party validation so funders, policymakers, and communities can hold us to account.
Leadership And Credibility
Execution starts with the people at the helm. Founder and CEO Dan Wiggins brings 36 utility patents and a track record of shipping more than 100 consumer products for companies like Microsoft, Polycom, Sonos, Masimo, and Dolby. Mike O’Brien, our CRO, has more than three decades of go-to-market leadership, including founding startups that punched above their weight against industry giants. Jim Humphries, our COO, cut his teeth running purchasing and operations at Kmart, earned Buyer of the Year at Walmart, and later held central merchandising and regional VP roles at Costco. This is a team built to build.
We’ve already checked the boxes that matter before scale: four issued utility patents, completed clinical trials, beta-stage hardware and software, and supply chain and pricing locked in, all on a clean, self-funded cap table. That combination, experienced operators with tangible progress, reduces risk for employers, partners, and investors, and it clarifies accountability as we expand access at home and, through the nonprofit, into regions clinics don’t reach.
Terms, Timeline, And How To Engage
The offering is Common Stock under Regulation CF (Section 4(a)(6)) on Netcapital at $8 per share, with a minimum investment of $104. The campaign runs until 11:59 p.m. ET on November 14, 2025, with a target minimum of $10,000 and a maximum of $1.2 million; the use-of-proceeds breakdown posted on the page includes production and tooling, final UX validation, marketing kickoff, extended fundraising, engineering, compensation, and intermediary fees. The page also links to the CPA review letter, the latest offering statement, and the Form C filed August 11, 2025, worth reading for anyone conducting diligence.
If this resonates, here’s how to help: invest; share the offering with your network; introduce retail, payer, and NGO partners; and explore employer pilots that put at-home hearing in the hands of workers and families who’ve delayed care for too long. The mechanics are straightforward, the filings are available, and the clock is running, let’s bring hearing home.
Risks, Responsibilities, And What We’ll Report
All forward-looking statements carry uncertainty. Please review Netcapital’s standard risk notices and the company’s filings, the Form C, CPA review letter, and latest offering statement, so you can weigh the opportunity with the same information I have. We’ll hold ourselves to public reporting on access and utilization: time-to-tune, device-in-use and daily-use persistence, and support response times; and on equity: geographic reach, affordability signals, and nonprofit deployments. That transparency is the point, architecture over slogans.
Real risks exist. Hardware supply must stay steady even as demand scales; retail adoption must align with a subscription model; regulation requires care; and complex cases must remain in clinical hands. Our mitigations are explicit: target mild to moderate loss; enable multiple listening profiles and at-home adjustments; backstop with 24/7 chat and extended phone support; pursue bundled months at the point of sale to reduce friction; and build on what’s already in place, four issued utility patents, completed clinical trials, beta-stage hardware/software, and supply chain and pricing locked in. We’ll measure, publish, and adjust in the open.
From Promise To Practice: Now Through November 14, 2025
When fitting moves home and takes minutes, more conversations are caught, more learning is sustained, and more work is retained. That’s the point. Shift clinical-grade hearing from the clinic to the home, remove the bottlenecks that suppress adoption, and unlock measurable gains, first in the U.S., then in countries with few or no audiologists.
If this resonates, I’m asking you to act: back the campaign, share it with your network, and help us stand up the nonprofit so access doesn’t stop at the border. The raise is live on Netcapital at https://netcapital.com/companies/doppler-labs and runs until 11:59 p.m. ET on November 14, 2025. Invest if you can, introduce partners if you will, and join us in bringing hearing home.
” Inclusion isn’t just the right thing to do — it’s a strategic advantage. “
Dr. Kirk Adams, Ph.D.
Advocate, Leader and Keynote Speaker on Disability Inclusion & Leadership
Leading the Way to Accessible Innovation
Innovative Impact, LLC Consulting
Managing Director
Impactful Workforce Inclusion Starts Here
American Foundation for the Blind
Immediate Past President & CEO
To create a world of no limits for people who are blind or visually impaired.
Connect With Me:
🌍 Website: https://drkirkadams.com
📧 Email: kirkadams@drkirkadams.com
📞 Phone: +1 (206) 660-1363
📃 Dissertation: https://drkirkadams.com/dissertation
🎙️ Podcasts: https://drkirkadams.com/podcasts
🎙️ Apple Podcasts: https://drkirkadams.com/podcasts-apple
🎙️ Amazon Music: https://drkirkadams.com/podcasts-amazon
🎙️ Spotify: https://drkirkadams.com/podcasts-spotify
🎙️ iHeart Radio: https://drkirkadams.com/podcasts-iheart-radio
📧 Subscribe: https://drkirkadams.com/subscribe
💬 Facebook: https://drkirkadams.com/facebook
💬 LinkedIn (Individual): https://drkirkadams.com/linkedin
💬 LinkedIn (Company): https://drkirkadams.com/linkedinpage
💬 Mastodon: https://drkirkadams.com/mastodon
✏️ Medium: https://drkirkadams.com/medium
🛜 RSS: https://drkirkadams.com/feed
💬 X (Formerly Twitter): https://drkirkadams.com/x
📽️ YouTube: https://drkirkadams.com/youtube
📍 Address: 140 Lakeside Avenue, Suite A, Seattle, Washington 98122-6538